AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Celularity Inc. Class A Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00P2RTT43
0.98▼ 0.07 (-6.89%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.05
Day's Range
0.91 – 1.14
52-Week Range
0.56 – 2.55
Volume
145.3K
Avg Volume
135.0K
Share Statistics
Shares Outstanding
Employees
123
Exchange
XNAS
Listed
2021-07-19
Share count as of October 19, 2026

Celularity Inc. Class A Common Stock (CELU) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Celularity Inc. Class A Common Stock (CELU)
What is Celularity Inc. Class A Common Stock's Market Cap?
Celularity Inc. Class A Common Stock's Market Cap is $31.7M, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's Enterprise Value?
Celularity Inc. Class A Common Stock's Enterprise Value is $65.0M, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's Price / Sales?
Celularity Inc. Class A Common Stock's Price / Sales is 1.7×, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's EV / Revenue?
Celularity Inc. Class A Common Stock's EV / Revenue is 3.5×, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's EV / EBITDA?
Celularity Inc. Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's Revenue (TTM)?
Celularity Inc. Class A Common Stock's Revenue (TTM) is $18.7M, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's Net Income (TTM)?
Celularity Inc. Class A Common Stock's Net Income (TTM) is -$45.9M, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's EBITDA?
Celularity Inc. Class A Common Stock's EBITDA is -$42.0M, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's Diluted EPS (TTM)?
Celularity Inc. Class A Common Stock's Diluted EPS (TTM) is -1.41, based on as-reported figures from SEC (XBRL) filings.
What is Celularity Inc. Class A Common Stock's EBITDA Margin?
Celularity Inc. Class A Common Stock's EBITDA Margin is -225.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CELUAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenues
Revenue
YoY growth-5.3%-66.3%-77.4%-43.2%
Cost of Revenue
Cost of Revenue
Research and Development Expense
Selling, General and Administrative Expense
Amortization of Intangibles——
Total operating expenses
Loss from operations
% of revenue-78.0%-263.5%-537.5%-244.1%
Other income (expense):
Interest and Dividend Income (Non-Bank)——
Interest expense
Change in fair value of warrant liabilities
Gain on SLS Settlement———
Loss on Helena Settlement———
Change in fair value of debt
Recognizing a net gain on settlement————
Sale of New Jersey state tax loss benefits——
Non-Operating Income (Expense)
Total other income (expense)
Income (loss) before income taxes—
Income Tax Expense————
Net income (loss)
% of revenue13.0%22.7%-593.6%-436.7%
Net income (loss) attributable to common shareholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)